Immunosuppression among HIV-1-positive patients attending for care: Experience from two large HIV centres in the United Kingdom

HIV Medicine

Volumn 11, Issue 2, 2010, Pages 114-120

  Harte, D ^a   Dosekun, O ^b   Sethi, G ^b   Chadborn, T ^c   de Ruiter, A ^b   Copas, A ^d   Edwards, S G ^a   Miller, R F ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral therapy; Factors associated with immunosuppression; HIV; Late presentation; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AMBULATORY CARE; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DELAYED DIAGNOSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; LONDON; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT FAILURE; TREATMENT REFUSAL; VIRAL LOAD;

EID: 73649106938     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00753.x     Document Type: Article

References (43)

1. Gazzard B. British HIV Association guidelines. Treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006, 7:487-503. on behalf of the BHIVA writing committee.
2. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/12030647583 66, The CD4 Surveillance scheme., 2006 survey results. Available at, (accessed December 2, 2008).
3. Egger M, May M, Chêne G. ART cohort collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
4. Hogg RS, Yip B, Chan KJ. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
5. http://ws1000-a.xuclh.nhs.uk/cgi-bin/patience.cgi?id=9dca4eb4-6cf9-4e0c- 971c-11e67703575d, The UK Collaborative Group for HIV and STI Surveillance, London., Health Protection Agency. Testing Times-HIV and other Sexually Transmitted Infections in the United Kingdom: 2007. Available at, (accessed December 16, 2008).
6. Sabin C, Smith CJ, Gumley H. Late presenters in the era of highly active antiretroviral therapy. AIDS 2004, 18:2145-2151.
7. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther 2007, 12:841-851.
8. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS 2006, 20:2371-2379.
9. Chadborn TR, Baster K, Delpech VC. No time to wait: how many HIV-infected homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS 2005, 19:513-520.
10. Castilla J, Sobrino P, De La Fuente L. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002, 16:1945-1951.
11. Sabin CA, Smith CJ, Youle M. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006, 20:67-71.
12. Emery S, Neuhaus JA, Phillips AN. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART Study. J Infect Dis 2008, 197:1133-1144. for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group
13. Sanders GD, Bayoumi AM, Sundaram V. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005, 352:570-585.
14. Stöhr W, Dunn D, Porter K. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003. HIV Med 2007, 8:135-141.
15. Brook MG, Curtis H, Johnson MA. Findings from the British HIV Association's national clinical audit of first-line antiretroviral therapy and survey of treatment practice and maternity care, 2002. HIV Med 2004, 5:415-420. on behalf of the British HIV Association Clinical Audit Committee.
16. Olsen C, Mocroft A, Kirk O. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007, 8:96-104.
17. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
18. El-Sadr WM, Grund B, Neuhaus J. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008, 149:289-299. for the SMART Study Group
19. Gazzard B. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2008). HIV Med 2008, 9:563-608. on behalf of the BHIVA Treatment Guidelines Writing Group.
20. Hartzell JD, Janke IE, Weintrob AC. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008, 62:246-255.
21. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007, 45:334-341.
22. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 2004, 19:1096-1103.
23. Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 2006, 66:769-789.
24. Mugavero M, Ostermann J, Whetten K. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDs 2006, 20:418-428.
25. Vranceanu AM, Safren S, Lu M. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDs 2008, 22:313-321.
26. Balfour L, Kowal J, Silverman A. A randomized controlled psycho-education intervention trial: improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care 2006, 18:830-838.
27. Maru DS, Bruce RD, Walton M. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav 2008, 12:284-293.
28. Berger S, Schad T, von Wyl V. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS 2008, 22:767-775.
29. Griffiths C, Miles K, Aldam D. A nurse- and pharmacist-led treatment advice clinic for patients attending an HIV outpatient clinic. J Adv Nurs 2007, 58:320-326.
30. Horberg MA, Silverberg MJ, Hurley LB. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008, 47:384-390.
31. Weiss L, French T, Finkelstein R. HIV-related knowledge and adherence to HAART. AIDS Care 2003, 15:673-679.
32. Simoni JM, Pearson CR, Pantalone DW. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006, 43((Suppl. 1)):S23-S35.
33. Burns FM, Johnson AM, Nazroo J. Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS 2008, 22:115-122.
34. Madge S, Olaiton A, Mocroft A, Philips A, Johnson M. Access to medical care one year prior to diagnosis in 100 HIV-positive women. Family Pract 1997, 14:255-257.
35. Klein D, Hurley LB, Merrill D, Quesenberry CP. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003, 32:143-152. for the Consortium for HIV/AIDS Interregional Research.
36. Simpson WM, Johnstone FD, Boyd FM. Uptake and acceptability of antenatal HIV testing: randomised controlled trial of different methods of offering the test. BMJ 1998, 316:262-267.
37. Paltiel AD, Walensky RP, Schackman BR. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006, 145:797-806.
38. Cohan D, Gomez E, Charlebois E. Patient perspectives and testing uptake with abbreviated standard pretest HIV counseling in the prenatal setting: a randomized-controlled, non-inferiority trial. Boston, MA, February 2008 [Abstract 535a]
39. http://www.bhiva.org/files/file1031097.pdf, British HIV Association, British Association of Sexual Health and HIV, British Infection Society., UK National Guidelines for HIV testing 2008. Available at, (accessed December 2, 2008).
40. Phillips A, Pezotti P. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004, 18:51-58. for the CASCADE Collaboration.
41. Nú̌ez M, Ascenio R, Valencia ME. Rate, causes, and clinical implications of presenting with low CD4 cell counts in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2003, 19:363-368.
42. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1227515298354, Health Protection Agency., HIV in the United Kingdom: 2008 report. Available at, (accessed January 31, 2009).
43. Chilton D, Neuhaus J, Palfreeman A, Edwards SG, Williams IG. Utility of CD4 count monitoring in patients on HAART who maintain viral load suppression-experience from the VS arm of the SMART Study. 2008;: 1-9.